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Blood Thinners Peri-Operatively: What to do?
Jad AL Danaf, MD, MPH (Facilitator), Anusha Govind, MD, Loheetha Ragupathi, MD, and Shuwei Wang, MD
INTRODUCTION
The population size today is increasing and becoming 
more of an aging population. This carries with it a package 
of chronic illnesses associated with aging and particularly 
the need for surgeries.
Atrial fibrillation is the most common arrhythmia causing 
approximately 20% of ischemic stroke cases with 
estimated annual costs of $6 billion in the United States1,2. 
Many patients undergoing surgeries are on blood thinning 
agents; either oral antiplatelet (AP) for established 
coronary artery disease of anticoagulants (AC) for atrial 
fibrillation or thromboembolic disease, putting them at 
risk of bleeding. It is estimated that about 5-15% of patients 
undergoing coronary stent implantation are expected to 
undergo a surgical procedure within 2 years3.
Hence, it is of utmost importance to be familiar with the 
perioperative management of AP and AC agents to 
balance the risks of thromboembolic events, ischemic 
cardiac events and bleeding. The key to such management 
is extensive benefit-risk discussions with patients and 
seamless coordination within a multidisciplinary team of 
surgeons, interventional proceduralists, anesthesiologists, 
hematologists, vascular medicine specialists, cardiologists, 
primary care physicians and nurses. We present a case 
based multidisciplinary panel discussion to facilitate better 
understanding of this topic. 
Before starting the case discussions, here are some 
definitions with respect to AC and AP agents:
• Interrupt: Omit one or more doses of the agent, 
based on the bleeding risk
• Bridge: Substitute the oral agent with a parenteral 
agent, based on the thrombotic risk
• Elective surgery: Can/should be delayed until the 
patient is medically stable.
• Urgent surgery: Needs to be done within 48 hours, 
needs quick attention and can be delayed for 
medical stability. This includes oncologic surgeries
• Emergent surgery: Needs to be done immediately, 
otherwise the patient will die.
The general approach to the perioperative management 
of blood thinners depends on 4 major steps4:
1. Estimating thromboembolic or ischemic risk
2. Estimating the bleeding risk (surgical, anesthesia type 
and patient factors)
3. Deciding whether and when to interrupt the AC or 
AP agents
4. Deciding whether there is a need for bridging 
therapy until the oral agent can be resumed
PERIOPERATIVE MANAGEMENT  
OF AC AGENTS
A modified risk stratification by Douketis et al of the 
consensus statement on the perioperative management 
of antithrombotic therapy is presented in Table 1 as 
published in 20124. Estimating the thromboembolic risk 
depends on three main illness categories: presence of a 
mechanical heart valve, atrial fibrillation and venous 
thromboembolic disease. Patients at very high risk of 
thromboembolic phenomena should either be continued 
on their AC agents perioperatively or bridged with a 
parenteral agent. Patients with low to moderate risk of 
thromboembolic phenomena can be safely managed 
perioperatively off their AC agents in case of high risk of 
bleeding that necessitates cessation of the AC agent.
The thrombotic risk drives the decision for bridging and the 
bleeding risk drives the decision for AC interruption. A 
risk-benefit ratio will dictate the most suitable plan of action 
in every patient, and in most scenarios, these decisions 
differ from case to case.
GRAND ROUNDS PANEL DISCUSSION 
PANELISTS
Mathew DeCaro, MD: Associate Professor of 
Cardiology, Director of the Coronary Cardiac Unit, 
Cardiology fellowship program director
John Doherty, MD: Professor of Cardiology
Gregary Markefka, MD: Associate Professor of 
Cardiology, Associate Director of the Coronary 
Cardiac Unit, Cardiology fellowship assistant 
program director
Geno Merli, MD: Professor of Vascular Medicine, 
Co-director of Jefferson Vascular Center
Srikanth Nagalla, MD, MS: Associate Professor of 
Medicine, Director, Clinical Hematology
Eric Schwenk, MD: Assistant Professor of 
Anesthesiology, Director of orthopedic anesthesia
Barry Ziring, MD: Clinical Associate Professor of 
Internal Medicine / Primary Care, Director of the 
division of Internal Medicine
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Table 1: Estimates of Thromboembolic Risks
Risk Category Mechanical valve AF VTE
Very high
• MV prosthesis
• Cage-ball or tilting disc AV
• Stroke/TIA: 6 months
• CHA2DS2-VASc 6-9
• Stroke/TIA: 3 months
• Rheumatic valve
• VTE: 3 months
• Severe thrombophilia  
(protein C or S deficiency,  
AT III deficiency, APLS)
High
Bileaflet AV +: AF, stroke/TIA,  
HTN, DM, CHF, >75 years old
CHA2DS2-VASc 4-5
• VTE: 3-12 months




Low-moderate Bileaflet AV + No other risk factors
CHA2DS2-VASc 2-3,  
no TIA/Stroke
VTE >12 months
Table 2: Estimates of Bleeding Risk
Risk category
Type of Surgery
• High risk* (cardiac, vascular, general surgery, kidney biopsy, polypectomy, bilateral knee, 
laminectomy, neurosurgery, urological)
• Low risk** (eye, cholecystectomy, hysterectomy, tooth extraction, endoscopy+biopsy, 
pacemaker, bronchoscopy + biopsies, knee, hip, arthroscopy)
Patient factors
• HAS-BLED score (hypertension, abnormal renal or liver function (two points for both), stroke, 
bleeding tendency, labile INRs, elderly age, and antiplatelet drugs or alcohol). Total 9 points.
• High risk: >3 points (HR 11.8, 95% CI 5.6-24.9) according to the BORDER registry
AF: atrial fibrillation; VTE: venous thromboembolism; MV: mitral valve; AV: aortic valve; TIA: transient ischemic attack; HTN: hypertension; DM: diabetes mellitus; 
CHF: congestive heart failure; AT: antithormbin; APLS: anti phospholipid syndrome; FV: factor five. Modified from Douketis JD et al.4
HR: Hazard ratio; *A high risk of bleeding is defined as a 2-4% risk of a major bleed within 2 days post-operatively; **A low risk of bleeding is defined as a 0-2% 
risk of a major bleed within 2 days post-operatively; Data from Spyropoulos et al6.
BID: twice a day; OD: once a day; TIA: transient ischemic attack; Data from Douketis et al4, Douketis et al7, Hirsh et al8.
Table 3: Bridging Therapy Management Peri-Operatively.
Bleeding risk Pre-operative Post-operative
Low
• Start on day-3 when stopped Warfarin day -5
• Omit dose on day 0
• Omit evening dose day -1 if BID dose
• 50% total dose if OD day-1
Resume therapeutic dose day 1, if 
hemostasis is secure
High
• Start on day-3 when stopped Warfarin day -5
• Omit dose on day 0
• Omit evening dose day -1 if BID dose
• 50% total dose OD day -1
Resume therapeutic dose days 2-3 if 
hemostasis is secure
OR
Low dose LMWH (30 or 40mg) when 
hemostasis is secure
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The bleeding risk is estimated based on surgical risk and 
patient’s risk. A major bleed is generally defined as bleeding 
that is fatal, intracranial, requires surgery to correct, lowers 
the hemoglobin by ≥2 g/dL, or requires transfusion of ≥2 
units of packed red blood cells5.
The goal of bridging is to minimize the patient’s time being 
off the oral anticoagulant for more protection against 
thromboembolic events. The commonly used agents are 
subcutaneous enoxaparin or parenteral unfractionated 
heparin which have similar safety profiles and efficacy. 
However, the risk of bleeding should be also factored in 
while deciding when to start and stop the bridging agent. 
The available consensus statements on bridging 
management are summarized in table3 4,7,8.
To note, most of the above recommendations are either 
class 2b or 2c recommendations, and cannot be considered 
guidelines as per the definition of guidelines; rather they 
reflect consensus statements based on the published 
available body of evidence.
The following are transcription of case discussions among 
the different experts regarding their recommendations for 
perioperative management of each patient.
Case 1: Warfarin
A 76-year-old female with non-valvular atrial fibrillation, 
hypertension, and prior stroke six months ago, receiving 
warfarin, requires elective hip replacement with neuraxial 
anesthesia; renal function is normal, and weight is 75 kg.
CHA2DS2-VASc=6 → Very high risk of thrombosis and high 
risk of bleeding
Dr. DeCaro: I tend to treat patients with a previous stroke 
aggressively irrespective of the time frame, so I would 
bridge this patient perioperatively.
Dr. Shwenck: We leave the decision to the orthopedic 
surgeons to determine the urgency of the procedure and if 
it can be delayed. We will still follow the currently available 
guidelines particularly concerning bridging.
Dr. DeCaro: We would also stop heparin at midnight prior 
to the procedure.
Dr.Merli: There is a study in Annals of Internal Medicine9 
that showed no anti-Xa effect on the morning of the surgery 
if the enoxaparin is stopped 24 hours prior to surgery.
Audience: When we try to risk assess, we multiply the 
likelihood by the impact of an illness. For example, if 100 
people had something done and 98% will do well, that’s a 
great likelihood ration. The impact of having something go 
bad, such as paralysis can affect the remaining 2%. 
Therefore, when we individualize care, patients should 
understand the risks that they are agreeing to and quoting 
likelihood of success is less meaningful that weighing both 
the likelihood of success and impact of failure.
Dr. Merli: I don’t think any orthopedic surgeon would allow 
their patients to receive a full dose of low molecular weight 
heparin (LMWH) on the same day after surgery, so they might 
recommend either lower doses or prophylactic doses.
Dr. Doherty: There was a survey that was recently sent out 
to the ACC members and asked :” Does your institution 
have a well structured process on how to manage periop-
eratively?”; and only one percent said they had a 
comprehensive well structured system on how to manage 
these patients perioperatively.                                                                                                                               
Audience: Can the panel comment on the appropriate 
time to stop heparin prior to surgery? We have had internal 
differences in opinions and recommendations.
Dr. Nagalla: The ACCP guidelines recommend stopping 
heparin 4-6 hours prior to surgery. For LMWH, the 
recommendation is at least 24 hours4. There are also some 
situations when we may need to use 40mg of enoxaparin 
instead of a therapeutic dose 24 hours prior to surgery in 
cases of high risk of bleeding in need for bridging therapy.
Suggested management plan for case 1:
• Stop warfarin day-5
• Preoperative bridging with LMWH day-3, with last 
dose on the morning of day-1.  
• Resume warfarin within 24 hours after surgery  
(usual dose).
• Postoperative low dose LMWH for VTE prevention 
within 24 hours after surgery until postoperative 
bridging is started.
• Postoperative bridging on postoperative day 2 or 3, 
when hemostasis is secured; continue for at least  
4-5 days, until the INR is therapeutic.
Case 2: Rivaroxaban
A 68-year-old female with non-valvular atrial fibrillation, 
hypertension, and congestive heart failure, receiving 
rivaroxaban 15 mg daily in the morning, requires a dental 
cleaning and two dental extractions; CrCl is 35 mL/min.
CHA2DS2-VASc score = 4 → high risk of thrombosis and 
low risk of bleeding
Dr. Merli: I would not bridge this patient and would stop 
rivaroxaban. She is on the lower dose, so the question is 
when to stop it. ASRA guidelines10 are not for dental 
procedures. Within 48 hours (4 half lives), rivaroxaban 
should be cleared, and 3 days for Xa inhibitors. I would 
restart rivaroxaban 24 hours after the procedure, and would 
think of an alternative drug for the future due to her low 
CrCl, such as warfarin.
Dr. Nagalla: I would treat her differently; I would not stop 
rivaroxaban and would use local pro-hemostatic agents 
such as tranexamic acid mouthwash. Hold dose on day of 
procedure, restart with next dose. 
Dr. Ziring: In the community they are less tolerant of 
bleeding so we tend to stop the oral AC sooner.
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Dr. Doherty: This would be a proceed-uninterrupted plan if 
a patient is taking Warfarin. The answer of this case might 
be different in 5 years due to the expanding data of direct 
acting anticoagulants (DOACS). Shall we delay the morning 
dose or omit the dose on that day?
Suggested management plan for case 2:
• Stop rivaroxaban on the day of the procedure.
• Use oral tranexamic acid mouthwash just before the 
procedure and two to three times that day after the 
procedure.
• Resume rivaroxaban the day after the procedure, 
after at least 24 hours have elapsed (assuming the 
dental extractions were uneventful).
Case 3: Apixaban
A 55 year old male with an unprovoked deep vein thrombosis 
(DVT) four months ago, receiving apixaban 5 mg twice 
daily, who requires a colonoscopy because of a personal 
history of premalignant colorectal polyps with planned 
polypectomy; renal function is normal. 
→ high risk of thrombosis and high risk of bleeding
Dr. Nagalla: It was noticed that the highest risk of thrombosis 
recurrence is within 3 months of the VTE. In this case, since 
the DVT is >3 months ago, we would focus more on the 
bleeding risk as compared to the thrombotic risk; Stopping 
Apixaban 48 hours prior to the procedure is reasonable, 
with no bridging, and resuming Apixaban after 24hours. We 
can also give them 2.5mg of Apixaban 12 hours after the 
procedure then resume full dose 24hours after the 
procedure.
Dr. Merli: I agree with Dr. Nagalla, I would stop it 48 hours 
prior to the procedure. The guidelines from ASRA are for 
regional anesthesia, so we have to be careful in interpreting 
these results. 
Audience: How would the answer change if the case is of 
a PE instead of a DVT?
Dr. Nagalla: Depends on the severity of a PE: Hemodynamic 
stability and if within the past 3 months, need for 
thrombolysis...etc. So even for PE, same risk stratification 
should take place.
Dr. Doherty: This case can be divided to what you do pre 
and postop, because with a normal renal function, you can 
hold one dose of Apixaban, emphasizing that you almost 
never bridge patients on DOACs. If it ends up being a large 
polyp, or a tiny polyp or no polyp, then post procedurally 
management differs.
Suggested management plan for case 3:
• Stop apixaban day-2
• No bridging
• Resume apixaban days 2-3 after the polypectomy/
colonoscopy.
Case 4: Warfarin
A 69-year-old male with chronic atrial fibrillation and 
hypertension on Warfarin, requires a Whipple surgery for 
pancreatic adenocarcinoma.
CHA2DS2-VASc score = 2 → low-moderate risk of 
thrombosis and high risk of bleeding
Dr. Ziring: Moderate risk is based on CHA2DS2-VASc risk 
but this patient has other risks of thrombosis: cancer and 
undergoing a major surgery. Therefore here are two 
approaches:
• Not bridge and restart coumadin + Sub-cutaneous 
heparin DVT prophylaxis
• LMWH before surgery, discontinue it prior to surgery, 
after surgery restart LMWH at lower dose, increase to 
full dose at time of discharge. Removes this 
confusion of pills and bridging.
Dr.Doherty: If the patient is ambulatory, the thrombotic risk 
is acceptably low. Risk is not stroke or systemic embolism; 
rather it is mainly of DVT. Therefore, post-op needs 
prophylactic dose prior to full dose enoxaparin or warfarin.
Dr. DeCaro: So post-op, transitioning to Warfarin, I would 
give DVT prophylaxis until INR is therapeutic on Warfarin.
Dr. Nagalla: There is an advantage of Warfarin post-op. 
Bowel resection; the advantage of using warfarin is that we 
have an INR to monitor as compared to DOACs. Patients 
on DOACs were excluded from most studies.
Suggested management plan for case 4:
• Stop Warfarin day-5
• No bridging
• Resume Warfarin day of surgery.
• Use sub-cutaneous heparin or LMWH for DVT 
prophylaxis on day of surgery onwards until INR is 
therapeutic
Case 5: Rivaroxaban and regional anesthesia
A 65 yo male with history of AF and hypertension taking 
rivaroxaban presents for primary total hip replacement. He 
denies any history of diabetes, coronary artery disease, 
stroke, or heart failure. Hemoglobin 14.0.
CHA2DS2-VASc score = 2 → low-moderate risk of 
thrombosis and low risk of bleeding
Dr. Schwenk: This is a common case. First thing, what is 
the bleeding risk? Primary hip replacement is important to 
distinguish from revision or more complicated hip surgeries. 
Thus the bleeding risk falls into the intermediate bleeding 
risk category. Second thing, what is the surgeon’s and 
anesthesiologist’s preference? We have an institutional 
practice that the surgeons prefer regional anesthesia, but I 
believe that the benefits of neuraxial anesthesia is 
exaggerated since most of the data is based on retrospective 
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data analysis. Third question is whether we need to bridge 
or not? And with what agent? 
ASRA are working on the 4th edition11 of anticoagulation 
management perioperatively and they published a draft 
table highlighting the recommended time intervals before 
and after neuraxial block or epidural catheter removal.
Dr. Merli: I would stop rivaroxaban for 2 days and restart it 
in the orthopedic dose of 10mg post procedurally, whenever 
the surgeons are ok with us restarting it. If anesthesiologists 
prefer 3 days, I would be ok with it as well. When do we go 
to the regular dose? Cardiologists may say in 2 weeks 
post-op? But we don’t know what the correct answer is. 
Some surgeons might even object to using rivaroxaban 
post-op. Should we use Warfarin instead? Or LMWH? These 
are nebulous questions. I would not bridge upfront and 
would restart rivoraxaban post-op.
Suggested management plan for case 5:
• Stop Rivaroxaban day-3 to reduce risk of spinal 
hematoma (may need longer with impaired CrCl or 
other agents that increase bleeding risk)
• No Bridging 
• Resume Rivaroxaban day +1, if team prefers to delay, 
consider LMWH or SQH for DVT prophylaxis
Perioperative management of AP agents
The general approach to managing patients on antiplatelet 
agents preoperatively is similar to that for Anticoagulant 
agents. Defining the fine balance between ischemic and 
bleeding risk remains a challenge in patients with coronary 
stents undergoing surgery treated with antiplatelet therapy. 
The risk of recurrent ischemic events for patients 
discontinuing or not adhering to aspirin treatment has been 
suggested to increase 3-fold12. Stent thrombosis is a serious 
complication that commonly presents with death or a 
significant nonfatal myocardial infarction. Ischemic events 
are more common after the premature discontinuation of 
a second antiplatelet agent such as clopidogrel and it can 
be explained by “withdrawal of protection”12. This can be 
accomplished by avoiding drug-eluting stents whenever 
possible, especially in patients with known poor adherence 
to medical therapy and with any anticipated surgeries.
Figure 1 highlights a suggested algorithm for perioperative 
management of patients on AP agents, as presented by Di 
Minno et al in 201313.
Low risk situations are defined as > 14 days post balloon 
angioplasty, > 6 weeks post bare metal stent and > 6 
months post drug eluting stent. If the patients is at low risk 
of major adverse cardiac events and have a low risk of 
bleeding, then the dual AP agents can be discontinued, but 
it is preferred if Aspirin is continued.
Figure 1. Algorithm for perioperative management of antiplatelet therapy.
Adapted from Di Minno et al.13
ADP: adenosine diphosphate; ASA: aspirin; PTCA: percutaneous transluminal coronary 
angioplasty; BMS: bare metal stent; DES: drug-eluting stent; MI: myocardial infarction; 
ST: stent thrombosis.
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Case 6: Dual AP agents post DES
68-year-old man with a sirolimus-eluting coronary stent 
inserted 4 months ago following NSTEMI. Now requires 
surgery for removal of a parotid neoplasm (adenocar-
cinoma → Urgent surgery
ASA, 81 mg + clopidogrel, 75 mg daily
CABG 8 years ago, Hypertension, Type 2 diabetes
→ high risk of thrombosis and low risk of bleeding
Dr. Marhefka: In patients who had an MI, the observational 
data shows that up to a year there are complications with 
non-cardiac surgeries. We don’t use sirolimus stents 
anymore, which are considered first generation stents. But 
if we had a patient with that such as in our case, and is 
beyond a year, we would be comfortable stopping the 
second AP agents but not the aspirin (ASA). Therefore, with 
a first generation stent, we would continue the surgery on 
ASA. We would push for surgery on double AP agents if it is 
4 months post stenting, or delay the surgery to at least 1 
year and then do the surgery only on ASA. If the case is of 
a second-generation stent, there is data with xerolimus and 
everolimus that showed evidence of 3 months of dual AP 
therapy is enough, but keep in mind that an NSTEMI was 
recent.
Dr. DeCaro: Our surgeons have reached a certain comfort 
level performing surgeries on dual AP agents.
Dr. Nagalla: One option might be to stop the AP agent, 
bridge with heparin and then restart the agent post-op.
Audience: This area needs more evidence to know how to 
manage AP agents. We have to respect the surgeon’s 
preferences, even if it is anecdotal or cultural rather than 
evidence based since they are the ones performing the 
surgery.
Suggested management plan for case 6:
• Optimal to delay surgery to at least 6 months  
after DES
• Since it is urgent due to active malignancy, and  
low risk of bleed, will proceed with surgery on  
DAPT without interruption.
CONCLUSION
Managing patients on blood thinners perioperatively can be 
very challenging and an optimal approach is an interdisci-
plinary discussion weighing the benefits to risks of stopping 
the agent or bridging whenever necessary. Patients should 
be fully informed of the risks of thrombosis versus bleeding 
when consenting to the plan. The available consensus 
statements have been serving as “guidelines”, but as our 
expert panelists have reminded us, they are class 2 
recommendations formed by expert consensus.  It is 
important to take these recommendations in the context of 
every patient for an individualized approach to treatment. 
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